GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicure Inc (TSXV:MPH) » Definitions » Short-Term Debt

Medicure (TSXV:MPH) Short-Term Debt : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Medicure Short-Term Debt?

Medicure's Short-Term Debt for the quarter that ended in Dec. 2023 was C$0.00 Mil.


Medicure Short-Term Debt Historical Data

The historical data trend for Medicure's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicure Short-Term Debt Chart

Medicure Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medicure Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Medicure Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Medicure Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Medicure's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicure (TSXV:MPH) Business Description

Traded in Other Exchanges
Address
2 - 1250 Waverley Street, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.

Medicure (TSXV:MPH) Headlines

No Headlines